KZA 0.00% 8.0¢ kazia therapeutics limited

Ann: Trading Halt, page-34

  1. 1,144 Posts.
    lightbulb Created with Sketch. 818
    IMO Kazia management is in-licencing the new drug, because researchers have conducted laboratory combination research with paxalisib and the data synergistically improves the outcome for the patients. A new eureka moment!

    A new paxalisib combination trial to be announced.at the same time.

    Regards.
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.